7604. Fair Allocation of Scarce Medical Resources in the Time of Covid-19.
作者: Ezekiel J Emanuel.;Govind Persad.;Ross Upshur.;Beatriz Thome.;Michael Parker.;Aaron Glickman.;Cathy Zhang.;Connor Boyle.;Maxwell Smith.;James P Phillips.
来源: N Engl J Med. 2020年382卷21期2049-2055页 7606. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia.
作者: Frederick J Raal.;David Kallend.;Kausik K Ray.;Traci Turner.;Wolfgang Koenig.;R Scott Wright.;Peter L J Wijngaard.;Danielle Curcio.;Mark J Jaros.;Lawrence A Leiter.;John J P Kastelein.; .
来源: N Engl J Med. 2020年382卷16期1520-1530页
Familial hypercholesterolemia is characterized by an elevated level of low-density lipoprotein (LDL) cholesterol and an increased risk of premature atherosclerotic cardiovascular disease. Monoclonal antibodies directed against proprotein convertase subtilisin-kexin type 9 (PCSK9) have been shown to reduce LDL cholesterol levels by more than 50% but require administration every 2 to 4 weeks. In a phase 2 trial, a twice-yearly injection of inclisiran, a small interfering RNA, was shown to inhibit hepatic synthesis of PCSK9 in adults with heterozygous familial hypercholesterolemia.
|